New and re-booked males with NGU, who attended the Department of Genitourinary Medicine at the Bristol Royal Infirmary were recruited. Those who had received antibiotics in the preceding two months were excluded. Routine samples were taken for the detection of Neisseria gonorrhoeae and C. trachomatis. Patients were randomly allocated to receive either ofloxacin 400 mg once daily for ten days or oxytetracycline 250 mg four times daily for ten days.-They were reassessed 14 and 21 days after initiation of therapy for clinical cure of urethritis.
Of the 265 men with NGU, 127 were treated with ofloxacin while 138 received oxytetracycline. Age, number of sexual partners in the preceding six months and condom use were similar in both groups.
Twenty-four men in the ofloxacin group and 36 in the oxytetracycline group were not assessable because of either default or sexual intercourse, during the follow-up period. Chi square test was used for statistical analysis. The results are summarised in the table.
Our study has shown that clinical cure rates for NGU did not differ significantly between the treatment groups. This is in agreement with previous studies which have compared ofloxacin with doxycycline2 and erythromycin.' Moreover, cure rates were not significantly different between the two antibiotics, for chlamydia-positive and chlamydianegative NGU. Patients tolerated ofloxacin well and found the single dose regimen convenient.
We conclude that ofloxacin is a safe and effective altemative in the treatment ofnon-gonococcal urethritis in men. 
